NCT03896958 (PIONEER) is a clinical trial in Cancer, All Types, sponsored by SpeciCare.

Who is sponsoring NCT03896958?

NCT03896958 is sponsored by SpeciCare.

What condition does NCT03896958 study?

NCT03896958 studies Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid.

Is NCT03896958 still recruiting?

NCT03896958 is currently status unknown. Last updated 4 December 2020.

Last reviewed 2020-12-04 · How we verify

NCT03896958: PIONEER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

Status unknown Last updated 4 December 2020

What this trial tests

trial in Cancer, All Types in 1,000 participants. Status unknown.

Timeline

21 March 2019

Primary endpoint
12 March 2024

12 March 2024

Quick facts

Lead sponsor	SpeciCare
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	21 March 2019
Primary completion	12 March 2024
Estimated completion	12 March 2024
Sites	1 location across United States

Conditions studied

Cancer, All Types — all drugs for Cancer, All Types →
Cancer of Liver — all drugs for Cancer of Liver →
Cancer of Stomach — all drugs for Cancer of Stomach →
Cancer of Head and Neck — all drugs for Cancer of Head and Neck →

Sponsor

SpeciCare

Who can join

Adults 1 Month to 99, any sex, with Cancer, All Types or Cancer of Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any medical facility. Tumor tissue is saved at time of biopsy or surgery in multiple formats, including fresh and cryopreserved as a living biospecimen. SpeciCare assists with access to clinical records in order to provide information back to the patient and the patient's clinical care team. The biospecimen tumor tissue is stored in a bio-storage facility and can be shipped anywhere the patient and the clinical team require for further testing. Additionally, the cryopreservation of the biospecimen allows for decisions about testing to be made at a later date. It also facilitates participation in clinical trials. The ability to return research information from this repository back to the patient is the primary end point of the study. The secondary end point is the subjective assessment by the patient and his or her physician as to the potential benefit that this additional information provides over standard of care. Overall the goal of PIONEER is to enable best in class functional precision testing of a patient's tumor tissue to help guide optimal therapy (to date this type of analysis includes organoid drug screening approaches in addition to traditional genomic profiling).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations.
Letai A, Bhola P, Welm AL. · · 2022 · cited 182× · PMID 34951956 · DOI 10.1016/j.ccell.2021.12.004
Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine.
Derouane F, van Marcke C, Berlière M, Gerday A, et al · · 2022 · cited 54× · PMID 36010869 · DOI 10.3390/cancers14163876
Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S, Sabaawy HE. · · 2021 · cited 44× · PMID 34587953 · DOI 10.1186/s12943-021-01426-3
Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.
Colao A, de Nigris F, Modica R, Napoli C. · · 2020 · cited 31× · PMID 33384663 · DOI 10.3389/fendo.2020.604341
Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment.
Vivarelli S, Candido S, Caruso G, Falzone L, et al · · 2020 · cited 29× · PMID 33291603 · DOI 10.3390/cancers12123636
Applications of organoid technology to brain tumors.
Wen J, Liu F, Cheng Q, Weygant N, et al · · 2023 · cited 26× · PMID 37248629 · DOI 10.1111/cns.14272
Lung Cancer Organoids: The Rough Path to Personalized Medicine.
Rossi R, De Angelis ML, Xhelili E, Sette G, et al · · 2022 · cited 21× · PMID 35954367 · DOI 10.3390/cancers14153703
The Potential Clinical Use of Stem/Progenitor Cells and Organoids in Liver Diseases.
Nikokiraki C, Psaraki A, Roubelakis MG. · · 2022 · cited 17× · PMID 35563716 · DOI 10.3390/cells11091410

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03896958 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SpeciCare
Last refreshed: 4 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03896958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing